Paul was Director, CEO and President of ICOS Corporation from 1999 until the sale to Eli Lilly and Company in 2007. He also served as Chairman from 2000 until 2007. ICOS was a top ten biotechnology company. Mr. Clark led the transition to a commercial organization achieving profitability while developing Cialis into a $1 billion product which became the market leader surpassing Viagra in many countries.
Paul has over 30 years of experience in the pharmaceutical and biotechnology industry. From 1984 to 1998, he worked in various capacities for Abbott Laboratories, a health care products manufacturer, retiring from Abbott Laboratories as Executive Vice President and Board member. In addition to other responsibilities during this time he ran the pharmaceutical business for fourteen years. Mr. Clark also held senior positions with Marion Laboratories, a pharmaceutical company, and Sandoz Pharmaceuticals (now Novartis).
Paul is a member of the board of Directors of Agilent Technologies, Catalent Pharma Solutions, and Cerevast Therapeutics.